Trials / Completed
CompletedNCT00445939
A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease
A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 15 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate the efficacy and safety of adalimumab for the induction of clinical remission in Japanese subjects with Crohn's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | adalimumab | 160 mg at Week 0, 80 mg at Week 2 |
| BIOLOGICAL | adalimumab | 80 mg at Week 0, 40 mg at Week 2 |
| BIOLOGICAL | placebo | Placebo at Week 0 and Week 2 |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2007-12-01
- First posted
- 2007-03-09
- Last updated
- 2011-06-27
- Results posted
- 2009-03-23
Locations
18 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00445939. Inclusion in this directory is not an endorsement.